Free tool
FAERS Monitor: Flavalta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216564 or its brand name (Flavalta, Epinephrine Bitartrate, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
22
Serious
19
86% of reports
Hospitalization
10
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6
- anaemia3
- diarrhoea3
- cytokine release syndrome2
- dyspnoea2
- emotional disorder2
- facial paralysis2
- fatigue2
- infusion related reaction2
- injection site pain2
- local anaesthetic systemic toxicity2
- poor quality product administered2
- product contamination physical2
- product use in unapproved indication2
- vomiting2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2016 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 7 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,137 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| local anaesthetic systemic toxicity | 2 | 1805.7 | 481.0 | 2,025 |
| product contamination physical | 2 | 753.5 | 200.9 | 844 |
| facial paralysis | 2 | 224.4 | 59.8 | 249 |
| poor quality product administered | 2 | 181.5 | 48.4 | 201 |
| cytokine release syndrome | 2 | 95.3 | 25.4 | 104 |
| emotional disorder | 2 | 62.0 | 16.5 | 67 |
| infusion related reaction | 2 | 28.8 | 7.7 | 30 |
| anaemiaSignal | 3 | 15.0 | 5.3 | 27 |
| product use in unapproved indication | 2 | 7.7 | 2.1 | 6 |
| off label useSignal | 6 | 6.6 | 3.3 | 24 |
| injection site pain | 2 | 6.2 | 1.7 | 4 |
| diarrhoeaSignal | 3 | 4.4 | 1.6 | 5 |
| vomiting | 2 | 4.1 | 1.1 | 2 |
| dyspnoea | 2 | 3.4 | 0.9 | 1 |
| fatigue | 2 | 2.5 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.